Product Images Lacosamide

This text presents a chart showing the median percentage reduction in seizure frequency per 28 days from baseline to the maintenance phase by dose in three different studies comparing placebo to Lacosamide at doses of 200, 400, and 600 mg/day. The results indicate that Lacosamide was associated with a statistically significant reduction in seizure frequency compared to placebo in all three studies.*

The text describes a figure labeled "Figure 2", which shows the proportion of patients in different responder rate categories for Lacosamide and Placebo groups in Studies 2, 3, and 4. The responder rate is equal to or greater, and the improvement is measured in percentages. The figure displays the percentage of patients who experienced a 100%, 75%, 50%, and 25% improvement or worsening in their condition, with corresponding numbers of patients for each drug dosage.*

This appears to be medication packaging information for Lacosamide Tablets, USP. The medication is in 100mg strength and could come with a medication guide for the patient. There are also NDC and serial numbers listed for tracking purposes. However, the rest of the information is difficult to decipher with lines of gibberish characters, and thus not available.*

This text is a medication label for Lacosamide tablets in 150mg dosage. It provides instructions on dosage, storage, and dispensing. It also includes a warning to keep the medication out of the reach of children. Additionally, it provides a medication guide and product information available online. The tablets are manufactured by Sun Pharmaceutical Industries, Ltd. in India and distributed in the United States by Sun Pharmaceutical Industries, Inc. The label includes a product code, NDC number, and lot number for tracking purposes.*